The possible link between psychological factors and length of cancer survival has generated a literature of contradictory Findings. Associations usually have not been found when general psychological symptoms are assessed. Associations usually have been found for predictors related to expressive versus repressive emotional coping (e.g., depression, "fighting spirit," hostility, and type C personality); however, even these associations have been relatively small, when compared with those for medical factors. Yet few studies have adequately controlled for medical and treatment-related factors. Purpose: Within a Cancer and Leukemia Group B (CALGB) national clinical trial of four adjuvant therapy regimens for stage II breast cancer (CALGB 8082), this study prospectively examined the contribution of potential psychological predictors to length of disease-free and overall survival over a 15-year period. Methods: Subjects were 280 women with stage II
Background:
The possible link between psychological factors and length of cancer survival has generated a literature of contradictory Findings. Associations usually have not been found when general psychological symptoms are assessed. Associations usually have been found for predictors related to expressive versus repressive emotional coping (e.g., depression, "fighting spirit," hostility, and type C personality); however, even these associations have been relatively small, when compared with those for medical factors. Yet few studies have adequately controlled for medical and treatment-related factors. Purpose: Within a Cancer and Leukemia Group B (CALGB) national clinical trial of four adjuvant therapy regimens for stage II breast cancer (CALGB 8082), this study prospectively examined the contribution of potential psychological predictors to length of disease-free and overall survival over a 15-year period. Methods: Subjects were 280 women with stage II breast cancer, out of a total of 899, who were randomly assigned to receive CMFVP (cyclophosphamide-methotrexate-fluorouracil-vincristine-prednisone) for two 6-week cycles or six 4-week cycles, then subsequently randomly assigned to receive or not to receive VATH (vinblastine-doxorubicin-thiotepa-fluoxymesterone). Subjects were recruited during the period between October 1980 and August 1984, inclusive, and followed until January 1996. Prior to chemotherapy, psychological symptoms were assessed using the Symptom Check List-90-Revised (SCL-90-R). SCL-90-R scores were trichotomized into categories representing high, medium, and low distress. Basic base-line sociodemographic data (including age, ethnicity, education, and marital status) and medical data (including lymph node status, estrogen receptor status, menopausal status, and performance status) were collected. Subjects with psychosocial data differed from those without psychosocial data solely in their higher percentage of classification in the mild limitation category of the Zubrod (Eastern Cooperative Oncology Group) performance status rating (subjects with psychosocial data: 14%; subjects without psychosocial data: 8%). Results: In stepwise Cox regression analyses that controlled for sociodemographic and medical variables, there was no significant predictive effect of the level of distress (as measured by the SCL-90-R trichotomized scores) on length of disease-free and overall survival of the study subjects. The possible link between psychological factors and cancer has given rise to a rapidly growing literature of contradictory findings. This literature may be categorized according to two major classes of prognostic factors: stress and psychological characteristics. It may be categorized further according to two major cancer outcomes: cancer diagnosis and cancer survival. Evidence of associations between acute stress and the onset of cancer (/), cancer relapse (2), and length of survival of cancer patients (3) has been obtained.
Several studies (4-7) have found a lack of association between psychological factors and length of survival of cancer patients when general psychological symptoms were used as predictors. However, Persky et al. (8) identified depression as a prognostic indicator of cancer mortality in a middle-aged male cohort of a case-control epidemiologic study of Western Electric Company workers. Yet, in a review of this and four similar studies with larger cohorts, Fox (9) has cautioned: ". .. the combined evidence is consistent with a null or weak relationship, the relative risks being distributed around a value of 1.0 or slightly more. It is clearly not consistent with a strong relationship between depressive symptoms and cancer among major segments of the population."
Expressive (versus repressive) emotional coping has been shown to be a significant predictor of cancer diagnosis and course. A "fighting spirit," consisting of higher facility for expression of anger, lower levels of denial of anxiety, and higher levels of active, noncompliant patient behavior, was reported to differentiate patients with benign breast lesions from those with malignant breast lesions (JO). Similarly, Hislop et al. (11) found an association between aspects of expressiveness and extroversion and survival in a sample of women with breast cancer at different stages. However, a more recent study by Buddeberg et al. (12) showed no relationship between coping strategies and the course of breast cancer.
Derogatis et al. (13) interpreted the higher levels of hostility that they observed in long-term versus short-term survivors of metastatic breast cancer as corroboration of the fighting-spirit hypothesis. Temoshok (14) used the construct of the type C personality, characterized by greater suppression of anger, passivity, and compliant patient behavior, to identify patients with a greater propensity for disease progression. In a study of melanoma patients, type C patients exceeded assertive patients on two indices of disease progression: tumor thickness and tumor invasiveness (14) . However, the findings of Kreitler et al. (75) argue against the role of repression as a personality correlate of cancer. They compared the levels of anxiety and repression before and after diagnosis in three groups of women: those undergoing non-cancerrelated surgery, those with benign breast lesions, and those with breast cancer. Only after diagnosis did breast cancer patients show significantly greater emotional suppression than the other two groups. These data suggest that heightened repression in cancer patients may be a reactive, rather than a causal, phenomenon.
The pursuit of psychological predictors of length of survival remains an open field of empirical inquiry in need of further research. In the studies described above, there has been a lack of control over potentially mediating treatment variables. In contrast, the present study was placed within a randomized phase III, national clinical trial of the Cancer and Leukemia Group B (CALGB) involving four adjuvant therapy regimens for stage II breast cancer (16, 17) . This trial (CALGB 8082) offered an ideal opportunity to assess psychological factors as antecedents within the overall prospective evaluation of disease-free survival and overall survival over a 15-year period. To date, this setting represents the largest controlled clinical trial of treatment within which possible psychological predictors of disease-free survival and overall survival were investigated.
Subjects and Methods

Research Procedures
Women with stage II breast cancer who were enrolled in a randomized trial (CALGB 8082) of four adjuvant chemotherapy regimens were studied (16, 17) . Following primary breast surgery, patients were initially randomly assigned to receive one of two CMFVP (cyclophosphamide-methotrexatefluorouracil-vincristine-prednisone) regimens-differing by a two 6-week-cycle schedule versus a six 4-week-cycle schedule of administration. Following either CMFVP regimen, patients were randomly assigned again either to receive or not to receive treatment with VATH (vinblastine-doxorubicinthiotepa-fluoxymesterone). Immediately before starting chemotherapy, all women were approached by the data managers at each of the institutions, requesting their participation in a study of psychosocial aspects of their illness and their reactions to it; this study had been approved by the Institutional Review Board. Once the women gave their informed written consent, they completed brief (5-to 10-minute) questionnaires concerning psychological symptomatology and sociodemographic status. Base-line treatment and other medical prognostic information were documented upon study entry. Disease-free survival and overall survival were determined over a 15-year period. Subjects were recruited during the period between October 1980 and August 1984, inclusive, and followed until January 1996.
The sample consisted of 280 women with psychological symptom data (31%) out of the total of 899 women entered in the study. There was a single statistically significant difference in medical and sociodemographic variables between the subgroups with and without psychological symptom data. The former subgroup had a higher percentage (14%) of patients in the Zubrod performance status category denoting mild limitation than did the latter (8%) (Fisher's exact test, P<.0OS). Reasons for nonaccrual were failure of data managers to request that patients complete the psychosocial questionnaires, patient refusal, or patient attrition from the trial.
Assessment
A selected pool of potential predictors and covariables was examined for inclusion in the main study analyses. This pool of variables consisted of (a) symptom scores from a psychological symptom questionnaire, the Symptom Check List 90-Revised (SCL-90-R) (18); (b) sociodemographic variables, including age, ethnicity, education, and marital status; and (c) selected medical prognostic and outcome variables, including lymph node status, estrogen receptor status, menopausal status, Zubrod performance status, and type of treatment. The assessments of these components are described below.
Symptom scores from a psychological symptom questionnaire. The SCL-90-R is a 90-item self-report questionnaire of psychological symptoms. Numerous studies (18) (19) (20) have demonstrated the validity and reliability of this questionnaire. In particular, the SCL-90-R was used in a study of patients with metastatic breast cancer and demonstrated higher levels of distress and hostility among long-term survivors than among short-term survivors (13) . The SCL-90-R items comprise nine subscales, corresponding to major symptom areas, including somatization, obsessive-compulsive symptoms, interpersonal sensitivity, depression, anxiety, hostility, phobic anxiety, paranoid ideation, and psychoticism. Each item is scored on a 5-point scale from "not at all" (score of 0) to "extremely" (score of 4). The subscale scores represented means across items. Since these individual subscale scores were strongly intercorrelated (i.e., Pearson r values ranging from .53 to .78; P-c.0001), the Global Severity Index (GSI), reflecting the patient's average item rating for all scales, was used as a single measure of global distress in lieu of scale scores. Based on community norms for women on the GSI, the GSI scores of the study subjects were trichotomized as follows: low distress, defined as a raw GSI score lower than 0.38 (corresponding to a score <0.5 standard deviation above the norm); medium distress, defined as a GSI raw score between 0.38 and 0.90 (corresponding to a score between 0.5 and 1.5 standard deviations above the norm); and high distress, defined as a raw GSI score of 0.91 or higher (corresponding to 1.5 standard deviations or greater than the norm). This tri- 21) , CMFVP regimen (i.e., two 6-week-cycle regimen versus six 4-weekcycle regimen), and subsequent VATH regimen (addition versus no addition). There were two indicators of survival outcome: length of disease-free survival and length of overall survival. Length of disease-free survival was defined as the interval from the time of entry in the trial to the time at which relapse-or non-relapse-related death occurred or as the interval from the time of entry in the trial to the time of last contact for disease-free survivors. Length of overall survival was defined as the interval from the time of entry in the trial to the time at which death or last contact occurred. A 15-year follow-up period, from October 1980 to January 1996, was used as the time frame of reference for this outcome.
Statistical Methods
To examine the relationship between these sociodemographic, medical, and psychological symptom variables and length of disease-free survival or overall survival, the Kaplan-Meier product-limit estimator (22) was used to estimate survival curves for the subgroups of patients defined by these parameters. The logrank test (23) was used to compare these subgroups with respect to disease-free survival or overall survival. The joint effects of covariables that were associated with disease-free survival or overall survival at a significance level of .25 in univariate analyses were examined by use of stepwise Cox regression analysis (24) . Interactions between GSI and important prognostic factors were also examined within the context of the Cox model. In these regression analyses, a significance level of . 10 was used to enter or to remove a covariable from the model. All P values resulted from two-sided tests.
Results
Description of the Sample
The medical and sociodemographic characteristics of the sample are presented in Table 1 . The sample was divided among women with one to three (43%), four to nine (33%), and 10 or more (24%) lymph nodes positive for metastasis. The majority of women were estrogen receptor positive (54%) and perimenopausal or postmenopausal (57%). The overwhelming majority were white (86%) and married (78%). The sample was fairly evenly divided among the three age subgroups (defined as women 40-49, 50-59, and 60-69 years old); a smaller percentage (19%) were under 40 years old. Sixty-three percent had a maximum of some high school education. Another 33% had a minimum of some college education.
Effects of Independent Variables on Length of Disease-Free Survival
There were 157 relapses or non-relapse-related deaths in the sample over the 15-year follow-up period. Maximum likelihood estimates of regression coefficients and risk ratios for the association between each independent variable and length of disease-free survival, adjusted for the other independent variables, are presented in Table 2 . Cox proportional hazards regression analysis revealed no significant disease-free survival effect for the GSI scores {see Fig. 1 for disease-free survival curves for the three GSI subgroups), and there were no significant in- *Cyclophosphamide-methotrexate-fluorouracil-vincristine-prednisone. tVinblastine-doxorubicin-thiotepa-fluoxymesterone. teraction effects between any prognostic factor and the GSI scores. However, a statistically significant disease-free survival effect was found for higher lymph node status and shorter length of diseasefree survival (regression coefficient, b = 0.83; risk ratio = 2.30; P<.0001). No statistically significant effects on diseasefree survival were obtained for any of the other sociodemographic or medical variables, including CMFVP and VATH treatment regimens.
Like other nonpsychiatric populations, the distribution of GSI scores in the sample was highly positively skewed. Forty-eight percent (n = 135) of the sample was concentrated in the bottom GSI category-with virtually (or literally) no symptoms. Only 12.5% (n = 35) fell within the top GSI category-with symptom levels at or exceeding the cutoff for psychiatric caseness.
Effects of Independent Variables on Length of Survival
There were 144 deaths in the sample over the 15-year follow-up period. Table  2 of regression coefficients and risk ratios for the association between each independent variable and length of survival, adjusted for the other independent variables. Cox proportional hazards regression analysis revealed no significant survival effect for the GSI scores (see Fig. 2 for overall survival curves for the three GSI subgroups). Statistically significant survival effects, however, were found for lymph node status, estrogen receptor status, and educational level. Specifically, there were strong associations between membership in the higher lymph node status subgroup (b = 0.82; risk ratio = 2.28; /><.0001), negative estrogen receptor status subgroup (b = -0.55; risk ratio = 0.57; /><.01), and lower educational level subgroup (b = 0.43; risk ratio = 1.54; P<.05) with shorter survival.
Discussion
Our study examined the role of psychological predictors in the multivariate medical context in which cancer survival was monitored. This context represents the largest prospective trial to date in which this issue has been investigated. The results failed to provide evidence that psychological factors contributed to the length of disease-free survival or overall survival in women with stage II breast cancer treated with adjuvant combination chemotherapy. The SCL-90-R used to assess psychological state included two factors, depression (8) and hostility (13) , for which disease-free survival effects have been reported. In contrast, there were expected associations obtained between lymph node status and length of diseasefree survival and between lymph node status and estrogen receptor status and length of overall survival. In addition, an association was obtained between educational level and length of overall survival-which has previously been reported in a sample of patients enrolled in a variety of CALGB protocols across diagnoses (25) .
Our results were consistent with the negative findings of other studies (4) (5) (6) (7) that have investigated the potential relationship between general psychological symptoms and length of survival. Our results were also consistent with the conclusion offered by Fox (926) in his critical review of the mixed findings reported in the literature on psychological factors in cancer diagnosis and progression and reiterated by Redd et al. (27) and Spiegel (28) . Fox (9) concluded that, if psychological factors did contribute to disease progression, their contribution was likely to be relatively small-and highly difficult to detect in the multivariate context of far more potent medical prognostic factors. In view of this constraint, separate subgroup analyses, controlling for lymph node status or estrogen receptor status, might have been helpful in further detecting the distinct role of psychological predictors. Subgroup samples, however, were too small in our study to make these analyses feasible.
Our results were partially consistent with the survival outcomes obtained in the clinical trial (CALGB 8082) within which this study was conducted (17) . As in this study, lymph node status was significantly associated with length of disease-free survival, and lymph node status and estrogen receptor status were sig- nificantly associated with length of overall survival. Our study, however, did not obtain the significant main effect on disease-free survival associated with the addition of VATH and the significant interaction effects on overall survival associated with the addition of VATH, within subgroups of patients with greater lymph node involvement, postmenopausal status, and postmenopausal and estrogen receptor-positive status. The failure to observe these associations in the clinical trial reported in our study was probably due to the 60% reduction in size between the total clinical trial sample and our study sample with psychosocial data. This smaller sample size did not afford the statistical power to detect interaction effects among patient subgroups.
Our results should also be viewed in terms of the limitations of the assessment and analytic methodology. First, general psychological symptoms, rather than theory-driven constructs, were used as predictors. Positive findings have generally been obtained when more specific constructs have been used as predictors. Furthermore, the use of general scales in a nonpsychiatric sample often results in a restricted range of extremely low scores, limiting the possibility of obtaining relationships between variables. On the GSI, as well as on all individual symptom subscales, our sample was highly positively skewed; roughly half of the patients were concentrated at the low extreme of the scales, with virtually (or literally) no symptoms.
Recent reviews of behavioral research (27, 28) have provided support for an association between psychological factors in and survival of patients with advanced cancer, arising in part from two new lines of research. First, two studies (29^0) have reported the predictive significance of patients' perceived quality of life for length of survival. The collection of prospective longitudinal quality-of-life data in clinical trials offers a highly promising approach to examining further the possible role of psychological factors in cancer survival. Second, two studies (31J2) have found that length of survival was significantly longer for patients randomly assigned to receive psychological treatment than for those given no psychological treatment. These findings may be attributable in part to psychological treatment enhancing patients' capacity to marshal favorable cancer treatment (e.g., type of treatment, treatment dosage, or degree of staff attention), akin to survival effects achieved by an educational chemotherapy compliance intervention reported by Richardson et al. (33) . These findings, however, may also be considered further evidence of the role of psychological factors, including enhanced assertiveness and/or activity as well as social support, in influencing cancer outcome.
Empirical support for a possible relationship between psychological factors and cancer survival remains variable and requires replication under controlled conditions in which the effects of key medical prognostic variables may be distinguished. Future research might focus on specific theory-driven constructs, rather than on general psychological symptoms. As in the present study, optimal conditions for identifying psychological predictors of survival should include the following: 1) a prospective time frame for determining which potential psychological predictors are clear antecedents of survival outcomes and 2) an experimental paradigm, such as a randomized trial testing psychological intervention^) hypothesized to promote survival, in which efficacy would be evaluated.
